Information about the expected shortage of the medicinal product Tienam powder for solution for infusion (imipinem, cilastatin)
Merck Sharp & Dohme d.o.o., the marketing authorisation holder for medicinal product Tienam, powder for solution for infusion (imipenem, cilastatin) has informed the Agency for medicinal products and medical devices (HALMED) about the expected shortage of the aforementioned product.
The shortage is due to certain difficulties in the manufacturing process and it is expected to last up to several months. Currently available product batches will be distributed on the Croatian market until they are out of stock.
There are other products from the same chemical-therapeutic subgroup currently available on the Croatian market.